White Rose University Consortium logo
University of Leeds logo University of Sheffield logo York University logo

Peroxisome proliferator-activated receptor gamma agonists in kidney disease - future promise, present fears

Mao, Z. and Ong, A.C.M. (2009) Peroxisome proliferator-activated receptor gamma agonists in kidney disease - future promise, present fears. Nephron Clinical Practice, 112 (4). pp. 230-241. ISSN 1660-2110

Full text not available from this repository. (Request a copy)

Abstract

The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-Y isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-Y agonist, in the management of type 2 diabetes mellitus. In this review, we discuss the pathogenic role of PPAR-Y in experimental models of kidney disease, clinical trials of thiazolidinediones in diabetic and non-diabetic kidney disease, recent safety concerns surrounding PPAR-Y agonists and reflect on their potential use in 'orphan' kidney diseases.

Item Type: Article
Keywords: PPAR-Y agonists; Thiazolidinediones; Kidney disease; Diabetes mellitus
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Clinical Sciences Division North (Sheffield) > Sheffield Kidney Institute
Depositing User: Miss Anthea Tucker
Date Deposited: 11 Aug 2009 08:58
Last Modified: 11 Aug 2009 09:00
Published Version: http://dx.doi.org/10.1159/000224789
Status: Published
Publisher: Karger
Refereed: Yes
Identification Number: 10.1159/000224789
URI: http://eprints.whiterose.ac.uk/id/eprint/9071

Actions (repository staff only: login required)